Background: Community pharmacies have grown to be an increasingly important provider of CLIA-waived tests, just second to physician offices as the venue with the most waivers. Yet, individual variation is still observed across states with respect to the percentage of pharmacies holding a CLIA-waiver, with a reported range of 10.7% in Massachusetts to 87.9% in Delaware. Objective: To identify how state laws can either impede or enhance access to POCT services by pharmacies by comparing the percentage of pharmacies in each state holding a CLIA-waiver to the legal model for POCT services in each state. Methods: Data from the U.S. Centers for Disease Control and Prevention CLIA Laboratory Search website reported on December 4, 2023, were used to determine the number of pharmacies holding CLIA-waivers in each state. This was then divided by the number of community pharmacies in each state, as reported in the 2023 National Community Pharmacy Association Digest, and then compared with 2 public reports on pharmacy CLIA laws. Results: States categorized as allowing pharmacists to independently perform CLIA-waived tests in public reports actually had a lower percentage of pharmacies with a CLIA-waiver (49.60%) than those categorized as not allowing CLIA-waived tests (60.19%). As many as 10 241 pharmacies hold a CLIA-waiver in states that did not affirmatively report that pharmacists ordering lab tests was allowed. Conclusion: The paradoxical finding is likely a result of the underreporting of pharmacist CLIA-waived testing authority given the complexity of pharmacy law relative to other professions. Simplifying pharmacy law through adoption of a “standard of care” regulatory approach may enhance patient access to POCT services moving forward.
KlepserMAdamsAJSrnisP, et alU.S. Community pharmacies as CLIA-waived facilities: prevalence, dispersion, and impact of access to testing. Res Soc Admin Pharm. 2016;12(4):614-621. doi:10.1016/j.sagepharm.2015.09.006.
3.
AdamsAJKlepserMEKlepserD.An update on community pharmacies as CLIA-waived facilities. Res Social Adm Pharm. 2016;12(4):666-667. doi:10.1016/j.sapharm.2016.03.007.
4.
KlepserNSKlepserDGAdamsJLAdamsAJKlepserME.Impact of COVID-19 on prevalence of community pharmacies as CLIA-Waived facilities. Res Social Adm Pharm. 2021;17:1574-1578. doi:10.1016/j.sapharm.2020.12.003.
5.
ZalupskiBElroumiZKlepserDG, et alPharmacy-based CLIA-waived testing in the United States: trends, impact, and the road ahead. Res Social Adm Pharm. 2024;20:146-151.
6.
RosenfeldLAEtkindPGrassoA, et alExtending the reach: local health department collaboration with community pharmacies in Palm Beach County, Florida for H1N1 influenza pandemic response. J Public Health Manag Pract. 2011;17(5):439-448.
AdamsAJFrostTWeaverK.Pharmacy Regulatory Innovation Index: benchmarking the regulatory environment in 10 western states. J Am Pharm Assoc (2003). 2021;61(5):e84-e89. doi:10.1016/j.japh.2021.05.003.
9.
DoucetteJLavinoJ.Ability of community pharmacist to independently perform CLIA-waived testing: a multistate legal review. Explor Res Clin Soc Pharm. 2021;2:100024.
10.
National Association of Boards of Pharmacy (NABP). 2024 Survey of Pharmacy Law. Chicago, IL: NABP.
11.
KlepserMEAdamsAJKlepserDG. Clinical service implementation in the face of initial regulatory uncertainty. J Am Pharm Assoc. 562016:492. doi:10.1016/j.japh.2016.04.563.
12.
AdamsAjEidDD.Toward collaborative practice, not collaborative practice agreements. Am J Health-Syst Pharm. 2023;81:zxad280. doi:10.1093/ajhp/zxad280.
13.
BacciJLColeyKCMcGrathKAbrahamOAdamsAJMcGivneyMS.Strategies to facilitate the implementation of collaborative practice agreements in chain community pharmacies. J Am Pharm Assoc (2003). 2016;56(3):257-265. doi:10.1016/j.japh.2016.02.014.
14.
AreAHauserRSpencerRSatterfieldJNguyenE.States’ pharmacist immunization authority and the impact on adult influenza vaccination rates. J Am Pharm Assoc (2003). 2022;62(5):1666-1670. doi:10.1016/j.japh.2022.04.017.
AdamsAJDering-AndersonAKlepserMEKlepserD.The roles of pharmacy schools in bridging the gap between law and practice. Am J Pharm Educ. 2018;82(4):6577. doi:10.5688/ajpe6577.
17.
AdamsAJ.Transitioning pharmacy to “standard of care” regulation: analyzing how pharmacy regulates relative to medicine and nursing. Res Soc Adm Pharm. 2018;15:1230-1235. doi:10.1016/j.sapharm.2018.10.008.
AdamsAJChopskiNL.Rethinking pharmacy regulation: core elements of Idaho’s transition to a “standard of care” approach. J Am Pharm Assoc (2003). 2020;60(6):e109-e112. doi:10.1016/j.japh.2020.07.013.
20.
HainesST.Pharmacists should be held to high standards, not hindered by bright-line rules. J Am Coll Clin Pharm. 2024;7(1):1074-1076. doi:10.1002/jac5.2038.
21.
AdamsAJChopskiNLAthay AdamsJ.How to implement a “standard of care” regulatory model for pharmacists. J Am Pharm Assoc. 2024;64(3). https://doi.org/10.1016/j.japh.2024.02.007.
